International Wex Technologies' (WXI) Tectin(TM) Study Results Show Efficacy In Pain Management; Phase IIa Final Results Announced At International Scientific Meeting
10/19/2005 5:11:14 PM
International Wex Technologies (TSX: WXI) today released the final results of its Phase IIa study of tetrodotoxin (Tectin(TM)), an investigational treatment for the management of severe cancer-related pain, at the 2nd Joint Scientific Meeting of the American Pain Society and the Canadian Pain Society being held in Vancouver, BC May 6-9, 2004.
The Phase IIa results demonstrate that Tectin(TM), administered intramuscularly for four days at the studied doses, is well tolerated and can relieve refractory cancer pain for up to two weeks in some patients. Consistent with the interim analysis, the final results show that almost three-quarters (72 per cent) of cancer pain patients experienced a clinically meaningful analgesic response.
The study was conducted in seven centers involving six Canadian cities: Saskatoon, Edmonton, Calgary, London, Montreal, and Toronto.
comments powered by